Abbreviated Infusion of Eptifibatide After Successful Coronary Intervention : The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) Randomized Trial

The purpose of this study was to assess whether the early discontinuation of eptifibatide infusion in nonemergent percutaneous coronary intervention (PCI) is associated with a higher frequency of periprocedural ischemic myonecrosis. The recommended regimen for eptifibatide is a double bolus followed...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the American College of Cardiology 2009-03, Vol.53 (10), p.837-845
Hauptverfasser:	FUNG, Anthony Y, SAW, Jacqueline, WEBB, John G, HAMBURGER, Jaap N, CARERE, Ronald G, BULLER, Christopher E, STAROVOYTOV, Andrew, DENSEM, Cameron, JOKHI, Percy, WALSH, Simon J, FOX, Rebecca S, HUMPHRIES, Karin H, AYMONG, Eve, RICCI, Donald R
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Angioplasty, Balloon, Coronary Aspirin - therapeutic use Biological and medical sciences Cardiology Cardiology. Vascular system Combined Modality Therapy Coronary Disease - therapy Coronary heart disease Coronary vessels Diseases of the cardiovascular system Double-Blind Method Drug Administration Schedule Drug therapy Drug Therapy, Combination Female Fibrinolytic Agents - adverse effects Fibrinolytic Agents - therapeutic use Heart Heart attacks Hemorrhage - chemically induced Hemorrhage - epidemiology Humans Infusions, Intravenous Male Medical sciences Middle Aged Peptides - administration & dosage Peptides - adverse effects Platelet Aggregation Inhibitors - administration & dosage Platelet Aggregation Inhibitors - adverse effects Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors Radiotherapy. Instrumental treatment. Physiotherapy. Reeducation. Rehabilitation, orthophony, crenotherapy. Diet therapy and various other treatments (general aspects) Retreatment Stents
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!